Management Team

Mr. Stephen S. Yoder joined Pieris as Chief Executive Officer in January 2010. Prior to joining Pieris, from July 2003 to December 2010 he led the intellectual property and legal departments at MorphoSys AG, a biotechnology company involved in the development and research of antibodies, as General Counsel. Prior to MorphoSys AG, from September 1999 to June 2003 he worked in several Washington, D.C. law firms, specializing in a life sciences intellectual property practice. Mr. Yoder holds degrees in molecular biology and Spanish from Grove City College and a Juris Doctorate, with honors, from The George Washington University Law School. As an attorney, he is licensed to practice before the United States Patent and Trademark Office, and in the jurisdictions of Maryland and Washington, D.C.

Dr. Hitto Kaufmann is a biopharma leader with over 20 years of experience in research, development and manufacturing with a track record in development of about 100 biological therapeutic entities. Prior to joining Pieris, Dr. Kaufmann spent five years at Sanofi, where he held several executive positions in Industrial Affairs and R&D. During his time there, he led efforts to build a strong cross-divisional end-to-end technology platform for Sanofi Biologics that included several strategic deals. He also went on to head Global Biopharmaceutics Development, managing over 700 employees across three sites tasked with drug substance and drug product technical development, analytics, clinical supply and release. Finally, he oversaw key strategic projects on digitalization and data sciences, as well as the integration of the Ablynx platform into the Sanofi network. Before his tenure at Sanofi, Dr. Kaufmann spent more than a decade at Boehringer Ingelheim, most recently in the Biopharmaceuticals division as Vice President, Process Science. He began his career as a Research Scientist at the Walter and Eliza Hall Institute in Melbourne. Dr. Kaufmann received his Ph.D. in Natural Science, focusing on cell culture technology, at the Swiss Federal Institute of Technology in Zurich and a Master of Science degree in biotechnology from the Technical University of Braunschweig and the Scripps Research Institute. He currently serves as Vice Chairman of the European Society of Animal Cell Technology and has authored over 25 peer reviewed publications.

Dr. Louis Matis joined Pieris as the Senior Vice President and Chief Development Officer in August 2015, bringing more than 30 years of experience in basic and clinical biomedical research, regulatory affairs, drug development and executive leadership. Prior to joining Pieris, Dr. Matis served since June 2011 as Executive Director, Strategic Evaluation at Alexion Pharmaceuticals, where he also served from 1993 to 2000, during which time he advanced to the position of CSO and had a leading role in discovering the first-in-class complement inhibitor monoclonal antibody Soliris® (eculizumab). Before re-joining Alexion in 2011, Dr. Matis served as CEO of CGI Pharmaceuticals, Inc. from 2000 to 2006, and of the Immune Tolerance Institute from 2007 to 2010. Under Dr. Matis’ leadership, CGI raised over $60 million in venture capital financing, established five partnerships with top tier pharmaceutical and biotechnology companies, and developed novel small molecule kinase inhibitors for both autoimmune disease and cancer indications. From 1977 until joining Alexion in 1993, Dr. Matis held senior research and clinical positions at the National Cancer Institute, National Institutes of Health, and the FDA Center for Biologics Evaluation and Research. Dr. Matis holds a B.A. from Amherst College and an M.D. from the University of Pennsylvania, Perelman School of Medicine. He completed his clinical training in Internal Medicine at the University of Chicago Hospitals and Clinics, and in Medical Oncology at the NCI. Dr. Matis is the author of over 120 publications in the fields of immunology, cell and molecular biology, and clinical medicine.

Dr. Shane Olwill has spent over a decade in oncology focused drug discovery with a specific interest in the development of novel biologics. Prior to joining Pieris, Shane was Director of Research at Fusion Antibodies Ltd where he was responsible for the discovery and development of multiple drug candidates. He is a named inventor on 16 patents and has published his research in many international peer review journals. Shane received his PhD in Molecular Hematology / Oncology from University of Ulster, following which he worked as an industrial postdoc in conjunction with University College Cork. Shane has a PgDip in Management Practice from DIT Business School and is a state qualified Medical Scientist.

Dr. Mary Fitzgerald brings to Pieris more than thirty years of respiratory drug development experience. Prior to joining Pieris, Dr. Fitzgerald, from February 2010 was the Executive Vice President of Respiratory at Pulmagen Therapeutics and from November 2002 to February 2010, Dr. Fitzgerald held various positions at Etiologics, Ltd., formerly Argenta Discovery, most recently as Executive Vice President of Respiratory, where she was responsible for clinical development of inhaled and oral drug candidates for both COPD and asthma. Previously, from 1988 to 2002 Dr. Fitzgerald was employed by Bayer Healthcare, as a Project Leader and later as Head of Pharmacology. Dr. Fitzgerald received her PhD from Sunderland University / Wellcome Laboratories and received her BSc Pharmacology from Bath University.

Dr. Christine Rothe has more than 17 years of experience in discovery, characterization and optimization of therapeutic protein drug candidates. She currently serves as VP Discovery and Alliance Management at Pieris. In this position she oversees technology development as well as the discovery process of selecting and profiling of Anticalin® proteins for Pieris proprietary and partnered programs. In addition, she holds responsibility for the Alliance Management team. She joined Pieris in 2010 as Senior Director Alliance Management. Prior to joining Pieris, she worked for 13 years at MorphoSys AG in various positions in R&D and Alliance Management, being responsible for technology development as well as therapeutic antibody project teams. She received a PhD in Cell Biology from the University of Regensburg, Germany. Before joining industry, she held a research position at the University of Regensburg.

Mr. Eckhard Niemeier is a highly-experienced deal maker in the life science sector, drawing on significant experience in corporate development, corporate strategy and financial analysis and valuation. Mr. Niemeier began his career at McKinsey & Company in their Healthcare Practice. He subsequently worked for MorphoSys AG as Director Business Development where he negotiated multiple product and technology licensing deals. Most recently, he was VP, Head of Corporate Licensing, at Grünenthal Pharma, being responsible for international licensing activities across all stages of drug development. Mr. Niemeier holds a M.Sc. in Biotechnology and completed his thesis in Molecular Biology at Human Genome Sciences, now part of GSK.

Mr. Ahmed Mousa joined Pieris in January 2016 and currently serves as Vice President, General Counsel and Corporate Secretary with responsibility for Pieris' legal matters, including licensing and corporate activities and the company's global patent portfolio. Prior to joining Pieris, Ahmed was an attorney with the law firm Covington & Burling LLP, where he represented pharmaceutical and biotechnology companies in a range of matters. Ahmed was also previously a law clerk at the U.S. Court of Appeals for the Third Circuit and an IP Associate at the law firm Kirkland & Ellis LLP. Ahmed obtained undergraduate degrees in Molecular Biology and Government from Cornell University with research experience prior to his legal career focused on tumor biology and angiogenesis. Ahmed graduated from Georgetown Law with honors, where he was the Editor-in-Chief of the Georgetown Journal of International Law.

Ingmar is Vice President of Clinical Development of the Company. Prior to joining Pieris, from 2013 through October 2017, Dr. Bruns led clinical development of several high priority oncology assets at Bayer Pharmaceuticals. Before his tenure at Bayer, Dr. Bruns served as an attending hematologist and oncologist as well as a basic, translational and clinical researcher at the University Hospital of Dusseldorf in Germany and Albert Einstein College of Medicine in New York. Dr. Bruns has authored over 50 papers in the field of hematology and oncology. He received his M.D. and Ph.D. from the University of Lubeck in Germany.

Mr. Thomas Bures joined Pieris Pharmaceuticals as the Vice President of Finance in December 2017. Tom has more than 20 years of finance experience and has spent the last several years managing finance organizations within the Healthcare and Life Sciences industry. Mr. Bures joins the Company from Genocea Biosciences Inc. (NASDAQ: GNCA) where he served as the VP Corporate Controller since 2015 and was responsible for the financial reporting, accounting, tax, treasury and insurance functions. Before joining Genocea, Mr. Bures worked for five years at PAREXEL International Corporation (formerly listed on NASDAQ: PRXL), most recently as the VP Assistant Controller. He was responsible for financial reporting, internal controls, and GAAP and statutory accounting for all legal entities. He started his career in Ernst and Young’s audit practice in 1996 and served multinational clients in the retail, manufacturing and banking industries. Tom received his B.S. in Accountancy from the College of the Holy Cross.

Mr. Frank Vollmering is Pieris Pharmaceuticals’ Vice President of Human Resources. Frank has more than 20 years of experience in international Human Resources across a diverse set of industries, such as semiconductors, software and consulting. Frank started his career at Intel Corporation (NASDAQ: INTC) where he supported the Central and Eastern European business operations. He then spent 5 years at Veritas Software Inc., a leading infrastructure software firm in the area of data availability solutions. Mr. Vollmering then joined Analog Devices Inc. (NASDAQ: ADI) where he was responsible for supporting the European Sales and Marketing Organization as well as Leadership Development on a global scale. Prior to joining Pieris Pharmaceuticals, Frank spent several years as an independent Leadership and Change Management Entrepreneur, consulting for businesses across multiple industries, including banking, pharmaceuticals, manufacturing and medical equipment. Frank holds an MSc in Business Administration from the University of Bayreuth, Germany.

Mr. Claus Schalper cofounded Pieris in 2001 and was CFO up to the listing of the Company in the US (2014) playing a key role in transforming Pieris to its current stage. He also served as CEO of Pieris executing first international pharma partnerships. Between 2015 and August 2017, he served as VP Finance of Pieris. Mr. Schalper began his career with Arthur Andersen and subsequently served as CEO for companies within the IT industry. He holds Master in Business Administration from the University of Bamberg, Germany.

Mr. Schalper is CEO and Cofounder of XL-protein GmbH.